PPARD and metabolic dysfunction-associated steatohepatitis: Seladelpar, a selective and potent peroxisome proliferator-activated receptor δ (PPARδ) agonist, has demonstrated hepatoprotective effects in clinical studies (3–5) but, like other single agents, may need to be combined with treatments that use complementary mechanisms for more effective resolution of NASH and fibrosis.